The Nomination Committee of Coegin Pharma has been appointed in accordance with the guidelines for the Nomination Committee adopted at the Annual General Meeting on May 22, 2025.
The following individuals have been appointed as members of the Nomination Committee for the 2026 Annual General Meeting:
The Nomination Committee is tasked with performing the duties assigned to it according to the Swedish Corporate Governance Code. The Committee is responsible for preparing proposals for the 2026 Annual General Meeting regarding the Chair of the Meeting, the Board of Directors, the Chair of the Board, the auditor, board and auditor fees, as well as any potential changes to the guidelines for the Nomination Committee.
The Annual General Meeting will be held on May 21, 2026 in Lund, Sweden.
Shareholders who wish to submit proposals to the Nomination Committee are welcome to do so no later than January 15, 2026. Proposals should be sent via email to info@coeginpharma.com.
The Nomination Committee's proposals will be presented in the notice of the Annual General Meeting, as well as on the company's website, www.coeginpharma.com.
For further information, please contact:
Jens Eriksson, CEO, Coegin Pharma AB
Email: je@coeginpharma.com
About Coegin Pharma
Coegin Pharma is a Swedish biotech company with cutting-edge innovations for hair and skin. The company is currently commercializing its patented hair growth innovation Follicopeptide® on a global scale. In development is NPP-4, a next-generation peptide that represents a novel approach to regulating skin pigmentation through advanced biotechnology.
Coegin Pharma's share is listed on NGM Nordic SME and dual-listed on Börse Stuttgart. The company is headquartered in Lund, Sweden.
More information - including subscription to company updates and links to social media - is available at coeginpharma.com